Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6 studies found for:    nanobody
Show Display Options
Rank Status Study
1 Recruiting Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects
Condition: Psoriasis
Interventions: Drug: MSB0010841 (Anti-IL-17A/F Nanobody);   Drug: Placebo matched to MSB0010841 (Anti-IL-17A/F Nanobody)
2 Completed Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura
Interventions: Biological: anti-vWF Nanobody;   Biological: Placebo
3 Completed Study to Assess Safety and Efficacy of Anti-Interleukin 6-receptor (IL6R) Nanobody in Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis
Interventions: Biological: ALX-0061;   Biological: Placebo
4 Terminated First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4
Condition: Healthy Volunteers
Interventions: Biological: ALX-0651;   Biological: Placebo
5 Completed Llama Antibody, Rotavirus Diarrhoea, Children
Conditions: Male Children;   6-24 Months Old With Rotaviral Diarrhoea;   Non-cholera Patients
Interventions: Drug: VHH batch 203027;   Drug: Placebo product
6 Completed ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers
Condition: RSV Infection
Interventions: Biological: ALX-0171;   Biological: Placebo

Indicates status has not been verified in more than two years